New inhaled therapy aims to slow ALS progression
NCT ID NCT02988297
Summary
This study is testing whether an inhaled mist called RNS60 can help people with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease). It will involve 140 adults with early-stage ALS to see if the treatment can slow the decline in their physical abilities and breathing. The main goal is to see if RNS60 improves daily function and reduces the need for breathing support.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.